DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OLANZAPINE

« Back to Dashboard

Clinical Trials for Olanzapine

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00000373	Treatment of Obsessive-Compulsive Disorder	Completed	National Institute of Mental Health (NIMH)	Phase 4	The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics). There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on type of OCD, determined by medical history and family member interviews. In Part 2, patients are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone, either haloperidol or an inactive placebo will be added to the FVX regimen; patients will take this drug combination for 4 weeks. Patients will be monitored throughout the trial.
NCT00000373	Treatment of Obsessive-Compulsive Disorder	Completed	University of Florida	Phase 4	The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics). There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on type of OCD, determined by medical history and family member interviews. In Part 2, patients are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone, either haloperidol or an inactive placebo will be added to the FVX regimen; patients will take this drug combination for 4 weeks. Patients will be monitored throughout the trial.
NCT00000374	Treatment for First-Episode Schizophrenia	Completed	National Institute of Mental Health (NIMH)	Phase 4	This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia.

Clinical Trial Conditions for Olanzapine

Condition Name

Condition Name for Olanzapine
Intervention	Trials
Schizophrenia	204
Bipolar Disorder	53
Schizoaffective Disorder	52

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Olanzapine
Intervention	Trials
Schizophrenia	216
Psychotic Disorders	82
Disease	74

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Olanzapine

Trials by Country

Trials by Country for Olanzapine
Location	Trials
United States	878
Canada	63
Spain	36
Germany	33
China	28

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Olanzapine
Location	Trials
New York	72
California	62
Texas	48
Ohio	47
Florida	42

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Olanzapine

Clinical Trial Phase

Clinical Trial Phase for Olanzapine
Clinical Trial Phase	Trials
Phase 4	147
Phase 3	102
Phase 2/Phase 3	10

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Olanzapine
Clinical Trial Phase	Trials
Completed	283
Recruiting	40
Terminated	31

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Olanzapine

Sponsor Name

Sponsor Name for Olanzapine
Sponsor	Trials
Eli Lilly and Company	82
National Institute of Mental Health (NIMH)	30
Pfizer	16

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Olanzapine
Sponsor	Trials
Other	363
Industry	236
NIH	45

Export unavailable in trial.
Subscribe for complete access.